Peptides: Prospects for Use in the Treatment of COVID-19

Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R. Molecules. 2020.

Organ: thymus-immune · Type: review · Peptides: Epitalon, Vilon, Thymogen, Thymopentin, Thymalin

A 2020 open-access review of peptide candidates for COVID-19 research — not a clinical trial, and not evidence that these peptides treat the disease.

Editorial summary of a 2020 Molecules review (MDPI, open access: doi:10.3390/molecules25194389). This is a prospects paper. It is not a randomized trial, not a treatment protocol, and not a claim that any peptide listed here treats or prevents COVID-19. Public pages cite PubMed; the DOI is the publisher’s OA record. Read the paper: PMID 32987757.

Methods

Narrative review. The authors summarize then-current (through September 2020) molecular accounts of SARS-CoV-2 entry and pathogenesis — ACE2, TMPRSS2, cathepsin L, CD147, cytokine-release hypotheses, and coagulopathy — and survey drug classes under discussion at the time (antimalarials, RAS blockers, protease inhibitors, polymerase inhibitors, IL-6 blockade, melatonin). They then compile published peptides and thymic preparations that, in prior literature, had been proposed to inhibit viral proteins, modulate immunity, or support bronchial epithelium. No new patient cohort, no new in-vitro antiviral assay, and no efficacy endpoint is generated by this article itself.

Findings

The authors group candidate peptides into three research buckets: fragments aimed at viral proteins (for example nsp10-derived sequences and spike heptad-repeat peptides HR1-1 and HR2-18, cited from earlier SARS-CoV work); immunomodulators, which they call the most promising group at low concentration — thymopentin (RKDVY), Thymogen (EW), Vilon (KE), Epitalon (AEDG), and the calf-thymus polypeptide complex Thymalin; and bronchoprotective sequences EDG (Chonluten) and AEDL (Bronchogen). They argue, from that prior work, that short immunomodulatory peptides might help restore cytokine balance and that bronchopulmonary peptides might be studied as adjuncts. They recount one published clinical observation of Thymalin added to standard care in a single severe COVID-19 case (Lukyanov, Kuznik, and Khavinson, 2020) — a case report in another journal, not a trial run here.

Nothing in this review establishes clinical benefit against SARS-CoV-2. Prospects language is not evidence of effect. Dosing, product use, and disease treatment are outside the scope of this page. Follow the PMID and the OA DOI.